Korean Market
EXCH
Whanin Pharm
★

Whanin Pharm Publishes 2025 Corporate Governance Report: Partial Gaps in Shareholder Rights, but Consistent Dividends and Voluntary Audit Committee Noted

 
EXCH
Whanin Pharm
★★★★

Preliminary Q1 2026: Sales KRW 71.2B, OP KRW 9.4B (YoY +18.2%, +77.7%)

 
PERI
Whanin Pharm
★★

Whan In Pharm Q1: Sales +18%, Profit +78%, Debt-Free, Dividend Sustained, 50B Lawsuit

 
OWNR
Whanin Pharm
★

Large Shareholding Report Template (No Content)